🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are increasing worldwide, with data suggesting more than 82 million instances per year. Notably increased rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the reality of rising global incidence, increasing antimicrobial resistance and the very limited available drugs at this time.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The WHO has designated it as a "critical concern". A tracking program found that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Approval

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in December for use against gonorrhoea. This STI can lead to major issues, including infertility. Experts anticipate that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This medication, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization represents a major breakthrough in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Research Study Data and Worldwide Availability

According to findings released by a major medical journal, the new drug cured more than 90% of cases of the STI. This establishes an equal footing with the existing first-line therapy, which uses an injection and a pill. The trial enrolled over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the authority to license and sell the drug in many low-income and middle-income countries.

Doctors directly involved have expressed optimism. Having a one-pill regimen like this is described as a "game-changer" for gonorrhoea control. This is considered crucial to lessen the impact of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.